B cells in autoimmune hepatitis: bystanders or central players?

Steinmann, Silja; Lohse, Ansgar W.; Binder, Mascha

doi:10.1007/s00281-022-00937-5

Cited by 16 publications

(14 citation statements)

References 226 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The depletion of B cells by rituximab is an alternative approach. However, the long-term use of these drugs in some patients may result in an increased risk of developing hypertension and diabetes [ 11 , 12 ].…”

Section: B Cells and Autoimmune Diseasesmentioning

confidence: 99%

Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update

Deng

Chan

et al. 2022

IJMS

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease and its related complications are becoming one of the most important health problems globally. The liver functions as both a metabolic and an immune organ. The crosstalk between hepatocytes and intrahepatic immune cells plays a key role in coordinating a dual function of the liver in terms of the protection of the host from antigenic overload as a result of receiving nutrients and gut microbiota antigenic stimulation via facilitating immunologic tolerance. B cells are the most abundant lymphocytes in the liver. The crucial role of intrahepatic B cells in energy metabolism under different immune conditions is now emerging in the literature. The accumulating evidence has demonstrated that the antibodies and cytokines produced by B cells in the microenvironment play key and distinct roles in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Herein, we have aimed to consolidate and update the current knowledge about the pathophysiological roles of B cells as well as the underlying mechanisms in energy metabolism. Understanding how B cells can exacerbate and suppress liver damage by exploiting the antibodies and cytokines they produce will be of great importance for designing B-cell targeting therapies to treat various liver diseases.

show abstract

Section: B Cells and Autoimmune Diseasesmentioning

confidence: 99%

Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update

Deng

Chan

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Der Nachweis von Autoantikörpern ist für keine der autoimmunen Lebererkrankungen pathognomisch und sollte immer im Zusammenhang und unter Beachtung sämtlicher klinischer Faktoren interpretiert werden, da sie auch bei anderen Autoimmunerkrankungen und sonstigen Lebererkrankungen auftreten können (s. Tab. 2 ) 4 , 5 .…”

Section: üBergreifende Aspekte In Der Diagnostik Und Therapieunclassified

“…Aktuell werden sowohl genetische als auch Umweltfaktoren diskutiert, die zur Dysregulation des Immunsystems mit der Folge einer T-Zell-getriebenen Zerstörung von Hepatozyten führt 12 . Das Vorhandensein einer selektiven IgG-Erhöhung sowie die Entwicklung von Autoantikörpern deuten auf eine Beteiligung von B-Zellen an der Pathogenese hin 5 .…”

Section: Autoimmune Hepatitis (Aih)unclassified

Autoimmune Lebererkrankungen – ein Update (Teil 1)

Steinmann¹,

Schregel²,

Schramm³

2022

Gastroenterologie up2date

Self Cite

View full text Add to dashboard Cite

“…In the absence of other APCs, activation of CD4 + T cells and T follicular helper (Tfh) can be initiated by B cells. It has been reported that B cell-derived cytokines have double-edged effects on AIH ( 8 ). On one hand, pro-inflammatory cytokines like type I interferons, tumor necrosis factor-alpha (TNF-α), and interleukin (IL) 6 contribute directly or indirectly to disease progression.…”

Section: Introductionmentioning

confidence: 99%

The immunological characteristics of TSPAN1 expressing B cells in autoimmune hepatitis

Chen

Qian

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Background and aimsTetraspanin proteins are closely related to the functional changes of B cells, including antigen presentation, production of cytokines, and transduction. We aim to explore the potential role of Tetraspanin 1 (TSPAN1) in the biological activities of B cells in AIH.Methods and resultsHerein, this study found that numbers of cells expressing TSPAN1 were significantly increased in AIH patients compared to PBC, chronic hepatitis B, and healthy control (P < 0.0001). Moreover, there was a positive correlation between numbers of TSPAN1+ cells and AIH disease severity (P < 0.0001). Immunofluorescence staining further confirmed that TSPAN1 was primarily expressed on CD19+ B cells. Flow-cytometric analysis showed that TSPAN1+ B cells secreted more inflammatory cytokines and expressed higher level of CD86 than TSPAN1- B cells. Furthermore, compared with TSAPN1- cells, the expression of CXCR3 on TSPAN1+ cells was also higher. Meanwhile, CXCL10, the ligand of CXCR3, was significantly elevated in the liver of AIH (P < 0.01) and had positive correlation with the quantities of TSPAN1 (P < 0.05). Interestingly, the numbers of TSPAN1+ B cells were decreased in AIH patients after immunosuppressive therapy.ConclusionsTSPAN1+ B cells in the liver may promote the progression of AIH via secreting cytokines and presenting antigens. The chemotactic movement of TSPAN1+ B cells toward the liver of AIH was possibly due to CXCR3 - CXCL10 interaction.

show abstract

B cells in autoimmune hepatitis: bystanders or central players?

Cited by 16 publications

References 226 publications

Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update

Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update

Autoimmune Lebererkrankungen – ein Update (Teil 1)

The immunological characteristics of TSPAN1 expressing B cells in autoimmune hepatitis

Contact Info

Product

Resources

About